

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN INSTITUTIONAL INC.,
Petitioner

v.

FRESENIUS KABI USA, LLC,
Patent Owner.

U.S. Patent No. 9,168,239 to Jiang *et al.*
Issue Date: October 27, 2015
Title: Levothyroxine Formulations

Inter Partes Review No.: IPR2017-00644

**Petition for *Inter Partes* Review of U.S. Patent No. 9,168,239 Under
35 U.S.C. §§ 311-319 and 37 C.F.R. §§ 42.1-.80, 42.100-.123**

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. OVERVIEW	1
III. STANDING (37 C.F.R. § 42.104(a); PROCEDURAL STATEMENTS)	2
IV. MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1))	3
A. Each Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))	3
B. Notice of Related Matters (37 C.F.R. § 42.8(b)(2))	3
1. Judicial Matters	3
2. Administrative Matters	4
C. Designation of Lead and Back-Up Counsel and Service (37 C.F.R. §§ 42.8(b)(3), 42.8(b)(4), 42.10(a), and 42.10(b)):	4
V. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFORE (37 C.F.R. § 42.22(a))	5
VI. THE '239 PATENT	5
A. Claim Construction	5
VII. PERSON OF ORDINARY SKILL IN THE ART & STATE OF THE ART	8
VIII. IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(b))	9
IX. INVALIDITY ANALYSIS	11
A. The Scope and Content of the Prior Art	11
1. Instability of Levothyroxine Salt Compositions	11
2. Mannitol was the Most Commonly Used Bulking Agent and was Used in Lyophilized Levothyroxine Sodium Compositions	16

3.	Mannitol’s Impact on the Stability of Lyophilized Levothyroxine Sodium Compositions was Known	17
B.	Ground 1: Claims 1–15 Would Have Been Obvious over the Abbott Label, Brower, Baheti, and Collier	21
1.	Claim 1	21
a.	A POSA Would Have Been Motivated to Reduce the Amount of Mannitol Below the 10 Milligrams Used in the Abbott label.....	21
(i)	Instability of Lyophilized Levothyroxine Compositions was Known	22
(ii)	Degradation of Levothyroxine by Mannitol was Known as was Reducing the Amount of Mannitol to Improve the Composition	23
b.	A POSA Would Have Had a Reasonable Expectation of Success.....	26
c.	Patent Owner’s Arguments during Prosecution of the Parent ’289 Patent Do Not Support Patentability	28
2.	Claims 2–5: Amount of Levothyroxine Sodium Converted to Liothyronine	36
a.	Claims 2 and 3.....	36
b.	Claims 4 and 5.....	39
3.	Claim 6: Amount of Mannitol	42
4.	Claims 7 and 8: Phosphate Buffer and 400 to 600 Micrograms of Dibasic Sodium Phosphate	43
a.	Claim 7.....	43
b.	Claim 8.....	43
5.	Claim 9: Sodium Salt of Levothyroxine.....	45
6.	Claim 10: Pharmaceutically Acceptable Liquid Carrier	46
7.	Claim 11: Concentration of Levothyroxine	46
8.	Claim 12: pH	47

9.	Claim 13: Method of Providing Levothyroxine to a Patient in Need	49
10.	Claims 14 and 15: Dosage of Levothyroxine	49
C.	Ground 2: Claims 1–15 Would Have Been Obvious over the APP Label, Brower, Baheti, and Collier.....	51
1.	Claim 1	51
a.	A POSA Would Have Been Motivated to Reduce the Amount of Mannitol Below the 10 Milligram Amount Used in Conventional Compositions	51
b.	A POSA Would Have Had a Reasonable Expectation of Success.....	52
2.	Claims 2–5: Amount of Levothyroxine Sodium Converted to Liothyronine	54
3.	Claim 6: Amount of Mannitol	55
4.	Claims 7 and 8: Phosphate Buffer and 400 to 600 Micrograms of Dibasic Sodium Phosphate	55
a.	Claim 7	55
b.	Claim 8	56
5.	Claim 9: Sodium Salt of Levothyroxine.....	57
6.	Claim 10: Pharmaceutically Acceptable Liquid Carrier.....	57
7.	Claim 11: Concentration of Levothyroxine.....	58
8.	Claim 12: pH	58
9.	Claim 13: Method of Providing Levothyroxine to a Patient in Need	59
10.	Claims 14 and 15: Dosage of Levothyroxine	59
D.	Ground 3: Claims 1–15 Would Have Been Obviousness over the Abbott Label, APP Label, Brower, Baheti, and Collier.....	60
1.	Claim 1	60

a.	A POSA Would Have Been Motivated to Reduce the Amount of Mannitol.....	61
2.	Claims 2–5: Amount of Levothyroxine Sodium Converted to Liothyronine	61
3.	Claim 6: Amount of Mannitol	61
4.	Claims 7 and 8: Phosphate Buffer and 400 to 600 Micrograms of Dibasic Sodium Phosphate	62
a.	Claim 7.....	62
b.	Claim 8.....	62
5.	Claim 9: Sodium Salt of Levothyroxine.....	63
6.	Claim 10: Pharmaceutically Acceptable Liquid Carrier.....	64
7.	Claim 11: Concentration of Levothyroxine.....	64
8.	Claim 12: pH	64
9.	Claim 13: Method of Providing Levothyroxine to a Patient in Need	65
10.	Claims 14 and 15: Dosage of Levothyroxine	65
E.	Objective Indicia of Non-Obviousness.....	65
1.	No Unexpected Results Over the Closest Prior Art.....	66
2.	Commercial Success.....	70
X.	CONCLUSION	70

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.